I. Sibum, P. Hagedoorn, C.O. Botterman, H.W. Frijlink and F. Grasmeijer In recent years there has been increasing interest in the pulmonary delivery of high dose dry powder drugs, such as antibiotics. Drugs in this class need to be dosed in doses far over 2.5 mg, and the use of excipients should therefore be minimized. […]

I. Sibum, P. Hagedoorn, H.W. Frijlink, F. Grasmeijer International Journal of Pharmaceutics, 2019, 11 (5) (DOI: 10.3390/pharmaceutics11050233)

M. Luinstra, A.W.F. Rutgers, T. van Laar, F. Grasmeijer, A. Begeman, V. Isufi, L. Steenhuis, P. Hagedoorn, A.H. de Boer, H.W. Frijlink Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease, Therapeutic Advances in Chronic Disease, 2019, 10 More info

M. Luinstra, V. Isufi, L. de Jong, A.W.F. Rutgers, P. Hagedoorn, J. Puttenstein, T. van Laar, H.W. Frijlink International Journal of Pharmaceutics, 2019, 567, p. 1-5 https://doi.org/10.1016/j.ijpharm.2019.118493